Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#91 / 200 Total
ISPR - Ispire Technology Inc - Stock Price Chart
TickerISPR [NASD, RUT]
CompanyIspire Technology Inc
CountryUSA
IndustryTobacco
Market Cap154.29MEPS (ttm)-0.49
P/E-EPS this Y-40.74%
Forward P/E-EPS next Y78.95%
PEG-EPS past 5Y-
P/S1.07EPS next 5Y-
P/B10.43EPS Q/Q-73.88%
Dividend-Sales Q/Q-12.74%
Insider Own67.42%Inst Own8.63%
Insider Trans-0.02%Inst Trans-6.20%
Short Float3.24%EarningsMay 12/b
Analyst Recom1.00Target Price7.15
Avg Volume69.60K52W Range2.09 - 7.93
Ispire Technology, Inc. engages in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company was founded on June 13, 2022 and is headquartered in Los Angeles, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Pryzbyla Steven P.CLO and SecretaryMar 17 '25Sale3.575001,785416,710Mar 19 04:30 PM
Pryzbyla Steven P.CLO and SecretaryMar 13 '25Sale4.036,13924,738417,210Mar 14 04:30 PM
Pryzbyla Steven P.CLO and SecretaryMar 12 '25Sale4.0061244423,349Mar 14 04:30 PM
ULH - Universal Logistics Holdings Inc - Stock Price Chart
TickerULH [NASD, RUT]
CompanyUniversal Logistics Holdings Inc
CountryUSA
IndustryTrucking
Market Cap686.77MEPS (ttm)3.17
P/E8.23EPS this Y-60.45%
Forward P/E8.55EPS next Y56.41%
PEG-EPS past 5Y29.78%
P/S0.40EPS next 5Y-
P/B1.06EPS Q/Q-88.54%
Dividend1.61%Sales Q/Q-22.26%
Insider Own74.80%Inst Own28.01%
Insider Trans0.00%Inst Trans1.78%
Short Float4.95%EarningsApr 24/a
Analyst Recom3.00Target Price29.00
Avg Volume53.60K52W Range20.60 - 53.29
Universal Logistics Holdings, Inc. engages in the provision of customized transportation and logistics solutions. It operates through the following segments: Contract Logistics, Intermodal, Trucking, Company-Managed Brokerage, and Other. The Contract Logistics segment delivers value-added and/or dedicated transportation services to support inbound logistics to original equipment manufacturers and major retailers on a contractual basis, generally pursuant to terms of one year or longer. The Intermodal segment caters local and regional drayage moves coordinated by company-managed terminals using a mix of owner-operators, company equipment and third-party capacity providers. The Trucking segment includes individual freight shipments coordinated by its agents and company-managed terminals using a mix of owner-operators, company equipment, and broker carriers. The Company-Managed Brokerage segment covers pick-up and delivery of individual freight shipments using broker carriers, coordinated by its company-managed operations. The Other segment focuses on support services to other subsidiaries. The company was founded in 1932 and is headquartered in Warren, MI.
KYTX - Kyverna Therapeutics Inc - Stock Price Chart
TickerKYTX [NASD]
CompanyKyverna Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap110.21MEPS (ttm)-3.37
P/E-EPS this Y-11.70%
Forward P/E-EPS next Y15.42%
PEG-EPS past 5Y-
P/S-EPS next 5Y-2.34%
P/B0.49EPS Q/Q8.09%
Dividend-Sales Q/Q-
Insider Own54.98%Inst Own25.54%
Insider Trans0.00%Inst Trans-15.68%
Short Float10.79%EarningsMay 13/a
Analyst Recom1.00Target Price17.20
Avg Volume414.08K52W Range1.78 - 11.40
Jun-30-25 09:00AM Kyverna Therapeutics Announces Appointment of New Chief Financial Officer (PR Newswire) -6.40%
May-28-25 04:02PM Kyverna Therapeutics to Present at the Jefferies Global Healthcare Conference (PR Newswire)
May-16-25 06:36AM Regeneron defeats Amgen in PCSK9 case; 2 cell therapy biotechs cut staff (BioPharma Dive) +6.42%
May-13-25 04:02PM Kyverna Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results (PR Newswire) -7.33%
Apr-17-25 07:38AM Notice to Long-Term Shareholders of Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Methode Electronics, Inc. (NYSE: MEI); ModivCare, Inc. (NASDAQ: MODV); and Monolithic Power Systems, Inc. (NASDAQ: MPWR) - Grabar Law Office Is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-27-25 04:02PM Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (PR Newswire) -5.80% -15.07%
Mar-24-25 09:13AM Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-21-25 11:29AM Kyverna: 2 Myasthenia Gravis Program Catalysts On Deck In 2025 (SeekingAlpha)
08:32AM Notice to Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Kyverna Therapeutics, Inc. (NASDAQ: KYTX); Mercury Systems, Inc. (NASDAQ: MRCY); and Rocket Lab USA, Inc. (NASDAQ: RKLB): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Mar-18-25 04:48PM Notice to Long-Term Shareholders of Archer-Daniels-Midland Co. (NYSE: ADM); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Kyverna Therapeutics, Inc. (Nasdaq: KYTX); and Mercury Systems, Inc. (Nasdaq: MRCY): Grabar Law Office is Investigating Claims on Your Behalf (GlobeNewswire)
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company, which engages in the provision of treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
AUID - authID Inc - Stock Price Chart
TickerAUID [NASD]
CompanyauthID Inc
CountryUSA
IndustrySoftware - Infrastructure
Market Cap66.14MEPS (ttm)-1.53
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y22.64%
P/S64.21EPS next 5Y-
P/B7.04EPS Q/Q-22.81%
Dividend-Sales Q/Q88.24%
Insider Own15.75%Inst Own16.94%
Insider Trans0.00%Inst Trans34.69%
Short Float4.51%EarningsMay 13/a
Analyst Recom-Target Price-
Avg Volume173.39K52W Range4.01 - 10.95
authID, Inc. engages in the delivery of secure, mobile, and biometric identity solutions. It operates through the Verified Authentication Business segment. The company was founded by Thomas R Snoke on September 21, 2011 and is headquartered in Denver, CO.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Szoke Thomas RobertChief Technology OfficerDec 11 '24Sale6.341,0006,34015,518Dec 12 08:00 AM
Szoke Thomas RobertChief Technology OfficerDec 10 '24Sale6.301,0006,30016,518Dec 12 08:00 AM
Thompson Michael CharlesDirectorDec 10 '24Buy6.495,00032,46283,677Dec 11 08:05 AM
Szoke Thomas RobertChief Technology OfficerDec 06 '24Sale6.251,5009,38117,518Dec 10 05:27 PM
Jisser KenDirectorDec 09 '24Buy6.488,00051,84051,475Dec 10 08:01 AM
FTHM - Fathom Holdings Inc - Stock Price Chart
TickerFTHM [NASD]
CompanyFathom Holdings Inc
CountryUSA
IndustryReal Estate Services
Market Cap35.55MEPS (ttm)-0.99
P/E-EPS this Y47.55%
Forward P/E16.00EPS next Y124.24%
PEG-EPS past 5Y-21.60%
P/S0.10EPS next 5Y-
P/B0.81EPS Q/Q21.94%
Dividend-Sales Q/Q32.10%
Insider Own58.34%Inst Own12.12%
Insider Trans5.32%Inst Trans64.39%
Short Float1.77%EarningsMay 13/a
Analyst Recom1.00Target Price1.50
Avg Volume63.81K52W Range0.65 - 3.37
Fathom Holdings, Inc. is a national, technology driven, end to end real estate services company, which engages in the provision of residential, brokerage, mortgage, title, insurance, and SaaS offerings for brokers and agents. It operates through the following segments: Real Estate Brokerage, Mortgage, Technology, and Corporate and Other Services. The company was founded by Joshua Harley in January 2010 and is headquartered in Cary, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Giuggio SamanthaChief Broker OfficerApr 01 '25Sale0.7212,8419,290104,689Apr 03 04:01 PM
Flanders Scott NDirectorMar 14 '25Buy0.72693,866500,0001,493,996Mar 18 04:09 PM
Murray Stephen H.DirectorMar 14 '25Buy0.72138,773100,000266,500Mar 18 04:00 PM
Giuggio SamanthaChief Broker OfficerJan 02 '25Sale1.506781,017117,690Jan 14 06:09 PM
Giuggio SamanthaChief Broker OfficerJan 10 '25Sale1.52160243117,530Jan 14 06:09 PM
CBLL - Ceribell Inc - Stock Price Chart
TickerCBLL [NASD, RUT]
CompanyCeribell Inc
CountryUSA
IndustryMedical Devices
Market Cap621.66MEPS (ttm)-
P/E-EPS this Y54.48%
Forward P/E-EPS next Y4.83%
PEG-EPS past 5Y-
P/S-EPS next 5Y33.13%
P/B3.41EPS Q/Q-
Dividend-Sales Q/Q-
Insider Own43.59%Inst Own47.23%
Insider Trans-0.72%Inst Trans5.40%
Short Float5.22%EarningsMay 08/a
Analyst Recom1.00Target Price30.83
Avg Volume399.77K52W Range10.01 - 32.75
Ceribell, Inc. is a commercial-stage medical technology company, which engages in the provision of transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point-of-Care EEG, which enables early detection and management of suspected seizure patients, promoting precise patient care and hospital-wide efficiencies, Clarity, an AI algorithm that interprets EEG in real-time, providing bedside alerts and continuous monitoring for status epilepticus, and EEG Portal, which makes it easy to remotely review EEG in real-time with pre-annotated EEG insights. The company was founded by Xing Juan Chao, Josef Parvizi, and Chris Chafe on August 29, 2014 and is headquartered in Sunnyvale, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chao XingjuanOfficerJul 07 '25Proposed Sale18.8025,000470,000Jul 07 01:07 PM
ROBERTSON REBECCA BDirectorJun 18 '25Sale17.8511,188199,70610,042Jun 20 12:31 PM
ROBERTSON REBECCA BDirectorJun 17 '25Sale17.637,445131,25521,230Jun 20 12:31 PM
Copp JoshuaFormer OfficerJun 18 '25Proposed Sale17.8511,188199,715Jun 18 01:23 PM
ROBERTSON REBECCA BDirectorJun 16 '25Option Exercise3.6120,00072,23248,675Jun 17 07:52 PM
THAR - Tharimmune Inc - Stock Price Chart
TickerTHAR [NASD]
CompanyTharimmune Inc
CountryUSA
IndustryBiotechnology
Market Cap4.50MEPS (ttm)-7.79
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y29.89%
P/S-EPS next 5Y-
P/B-EPS Q/Q65.67%
Dividend-Sales Q/Q-
Insider Own55.13%Inst Own2.56%
Insider Trans37.65%Inst Trans435.42%
Short Float1.65%EarningsFeb 26
Analyst Recom1.00Target Price5.00
Avg Volume89.22K52W Range0.95 - 6.39
Jun-17-25 08:01AM Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors (ACCESSWIRE) +9.09%
May-19-25 08:01AM Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +7.79%
May-06-25 08:01AM Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback (ACCESSWIRE) +5.77%
May-01-25 08:01AM Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences (ACCESSWIRE) -10.40%
Apr-30-25 08:01AM Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors (ACCESSWIRE) +16.89%
Apr-28-25 08:01AM Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback (ACCESSWIRE) +13.34%
Apr-15-25 09:00AM Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors (ACCESSWIRE)
Apr-07-25 08:00AM Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology (ACCESSWIRE)
Mar-31-25 08:00AM Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure (ACCESSWIRE)
Mar-04-25 07:00AM Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology (ACCESSWIRE)
Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. It also develops TH104, which is known to suppress chronic, debilitating pruritus or uncontrollable itching in PBC, a rare and orphan liver disease with no known cure. The company was founded on March 28, 2017 and is headquartered in Bridgewater, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gravitas Capital LPExecutive ChairmanJun 20 '25Buy1.48337,838500,000732,424Jun 23 09:29 PM
Parikh SanamDirectorJun 20 '25Buy1.451,0001,4501,770Jun 23 07:34 PM
Appajosyula SireeshChief Executive OfficerJun 20 '25Buy1.4861,49690,97364,868Jun 23 07:31 PM
Parikh SanamDirectorMay 15 '25Buy1.307701,001770May 16 04:15 PM
MILBY RANDYCEODec 19 '24Buy2.124,6009,75217,534Dec 20 08:00 PM
INMB - INmune Bio Inc - Stock Price Chart
TickerINMB [NASD, RUT]
CompanyINmune Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap61.15MEPS (ttm)-1.95
P/E-EPS this Y30.94%
Forward P/E-EPS next Y9.71%
PEG-EPS past 5Y-23.07%
P/S1223.00EPS next 5Y47.53%
P/B1.78EPS Q/Q29.22%
Dividend-Sales Q/Q257.14%
Insider Own28.90%Inst Own28.05%
Insider Trans0.00%Inst Trans-4.55%
Short Float38.40%EarningsMay 08/a
Analyst Recom2.43Target Price4.92
Avg Volume2.39M52W Range1.89 - 11.64
INmune Bio, Inc. is a clinical stage biotechnology company, which engages in developing new immunotherapies that reprogram the immune system to fight cancer and Alzheimer's disease. Its product pipeline includes INKMUNE-Cancer, INB03-Cancer, XPRO1595-Alzheimer and TRD, and LIVNate. The company was founded by Mark Lowdell on September 25, 2015 and is headquartered in Boca Raton, FL.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Moss David JChief Financial OfficerSep 30 '24Buy5.2910,00052,8681,285,869Sep 30 04:01 PM
Tesi Raymond JosephPresident and CEOSep 12 '24Buy6.3815,38098,0481,554,106Sep 16 08:48 PM
Moss David JChief Financial OfficerSep 12 '24Buy6.387,69049,0241,275,869Sep 16 08:47 PM
PEPG - PepGen Inc - Stock Price Chart
TickerPEPG [NASD]
CompanyPepGen Inc
CountryUSA
IndustryBiotechnology
Market Cap36.32MEPS (ttm)-3.14
P/E-EPS this Y9.16%
Forward P/E-EPS next Y21.81%
PEG-EPS past 5Y-116.35%
P/S-EPS next 5Y12.87%
P/B0.40EPS Q/Q-46.99%
Dividend-Sales Q/Q-
Insider Own15.05%Inst Own81.35%
Insider Trans1.17%Inst Trans2.79%
Short Float6.49%EarningsMay 08/b
Analyst Recom1.60Target Price8.00
Avg Volume242.76K52W Range0.88 - 19.30
PepGen Inc. develops oligonucleotide therapies. It is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. The company was founded in March 26, 2018 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
STRECK PAULEVP, Head of R&DMay 30 '25Buy1.248,37510,39327,805Jun 02 05:03 PM
McArthur James GPresident and CEOApr 17 '25Buy1.3510,00013,550113,913Apr 22 07:01 AM
McArthur James GPresident and CEOApr 08 '25Buy1.1541,50047,725103,913Apr 09 07:40 AM
DeLena Mary BethGeneral CounselFeb 26 '25Sale1.681,4322,4061,568Feb 26 08:24 PM
Donnelly NoelChief Financial OfficerFeb 26 '25Sale1.681,5272,5651,673Feb 26 08:12 PM
SLAB - Silicon Laboratories Inc - Stock Price Chart
TickerSLAB [NASD, RUT]
CompanySilicon Laboratories Inc
CountryUSA
IndustrySemiconductors
Market Cap4.55BEPS (ttm)-5.11
P/E-EPS this Y137.44%
Forward P/E56.09EPS next Y291.63%
PEG-EPS past 5Y-
P/S6.94EPS next 5Y-
P/B4.25EPS Q/Q47.01%
Dividend-Sales Q/Q67.06%
Insider Own2.48%Inst Own106.04%
Insider Trans-2.37%Inst Trans1.54%
Short Float5.59%EarningsMay 13/b
Analyst Recom2.17Target Price142.78
Avg Volume427.85K52W Range82.82 - 160.00
Silicon Laboratories, Inc. engages in providing and developing analog-intensive and mixed-signal integrated circuits. It focuses on wireless development platform and product portfolio for the internet of things based on Bluetooth, sub-GHz proprietary technologies, Wi-SUN, Thread, Wi-Fi, Zigbee, and Z-Wave. The company was founded by Navdeep S. Sooch, David R. Welland, and Jeffrey W. Scott in August 1996 and is headquartered in Austin, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CONRAD ROBERT JSr VP and General ManagerMay 16 '25Sale131.204,029528,60525,380May 19 01:29 PM
Johnson Robert MatthewPresident & CEOMay 16 '25Sale131.205,879771,32573,688May 19 01:28 PM
Johnson Robert MatthewOfficerMay 16 '25Proposed Sale131.205,879771,325May 16 10:31 AM
CONRAD ROBERT JOfficerMay 16 '25Proposed Sale131.204,029528,605May 16 10:30 AM
CONRAD ROBERT JSr VP Worldwide OperationsMay 13 '25Sale130.001,172152,36015,972May 14 12:22 PM
15678910111213141520